Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Fcγ Receptors Contribute to the Antiviral Properties of Influenza Virus Neuraminidase-Specific Antibodies.

Job ER, Ysenbaert T, Smet A, Van Hecke A, Meuris L, Kleanthous H, Saelens X, Vogel TU.

MBio. 2019 Oct 22;10(5). pii: e01667-19. doi: 10.1128/mBio.01667-19.

2.

Comparison of adjuvants to optimize influenza neutralizing antibody responses.

Rudicell RS, Garinot M, Kanekiyo M, Kamp HD, Swanson K, Chou TH, Dai S, Bedel O, Simard D, Gillespie RA, Yang K, Reardon M, Avila LZ, Besev M, Dhal PK, Dharanipragada R, Zheng L, Duan X, Dinapoli J, Vogel TU, Kleanthous H, Mascola JR, Graham BS, Haensler J, Wei CJ, Nabel GJ.

Vaccine. 2019 Sep 30;37(42):6208-6220. doi: 10.1016/j.vaccine.2019.08.030. Epub 2019 Sep 5.

PMID:
31493950
3.

Broadened immunity against influenza by vaccination with computationally designed influenza virus N1 neuraminidase constructs.

Job ER, Ysenbaert T, Smet A, Christopoulou I, Strugnell T, Oloo EO, Oomen RP, Kleanthous H, Vogel TU, Saelens X.

NPJ Vaccines. 2018 Nov 29;3:55. doi: 10.1038/s41541-018-0093-1. eCollection 2018.

4.

Development of a Pan-H1 Influenza Vaccine.

Darricarrère N, Pougatcheva S, Duan X, Rudicell RS, Chou TH, DiNapoli J, Ross TM, Alefantis T, Vogel TU, Kleanthous H, Wei CJ, Nabel GJ.

J Virol. 2018 Oct 29;92(22). pii: e01349-18. doi: 10.1128/JVI.01349-18. Print 2018 Nov 15.

5.

Antibodies Directed toward Neuraminidase N1 Control Disease in a Mouse Model of Influenza.

Job ER, Schotsaert M, Ibañez LI, Smet A, Ysenbaert T, Roose K, Dai M, de Haan CAM, Kleanthous H, Vogel TU, Saelens X.

J Virol. 2018 Jan 30;92(4). pii: e01584-17. doi: 10.1128/JVI.01584-17. Print 2018 Feb 15.

6.

Impact of age and pre-existing influenza immune responses in humans receiving split inactivated influenza vaccine on the induction of the breadth of antibodies to influenza A strains.

Nuñez IA, Carlock MA, Allen JD, Owino SO, Moehling KK, Nowalk P, Susick M, Diagle K, Sweeney K, Mundle S, Vogel TU, Delagrave S, Ramgopal M, Zimmerman RK, Kleanthous H, Ross TM.

PLoS One. 2017 Nov 1;12(11):e0185666. doi: 10.1371/journal.pone.0185666. eCollection 2017.

7.

Elicitation of Protective Antibodies against a Broad Panel of H1N1 Viruses in Ferrets Preimmune to Historical H1N1 Influenza Viruses.

Carter DM, Darby CA, Johnson SK, Carlock MA, Kirchenbaum GA, Allen JD, Vogel TU, Delagrave S, DiNapoli J, Kleanthous H, Ross TM.

J Virol. 2017 Nov 30;91(24). pii: e01283-17. doi: 10.1128/JVI.01283-17. Print 2017 Dec 15.

8.

Application of replication-defective West Nile virus vector to non-flavivirus vaccine targets.

Giel-Moloney M, Vaine M, Zhang L, Parrington M, Gajewska B, Vogel TU, Pougatcheva SO, Duan X, Farrell T, Ustyugova I, Phogat S, Kleanthous H, Pugachev KV.

Hum Vaccin Immunother. 2017 Dec 2;13(12):2982-2986. doi: 10.1080/21645515.2017.1373920. Epub 2017 Sep 19.

9.

Long-Lasting Cross-Protection Against Influenza A by Neuraminidase and M2e-based immunization strategies.

Schotsaert M, Ysenbaert T, Smet A, Schepens B, Vanderschaeghe D, Stegalkina S, Vogel TU, Callewaert N, Fiers W, Saelens X.

Sci Rep. 2016 Apr 13;6:24402. doi: 10.1038/srep24402.

10.

Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses.

Carter DM, Darby CA, Lefoley BC, Crevar CJ, Alefantis T, Oomen R, Anderson SF, Strugnell T, Cortés-Garcia G, Vogel TU, Parrington M, Kleanthous H, Ross TM.

J Virol. 2016 Apr 14;90(9):4720-4734. doi: 10.1128/JVI.03152-15. Print 2016 May.

11.

Murine responses to recombinant MVA versus ALVAC vaccines against tumor-associated antigens, gp100 and 5T4.

Hanwell DG, McNeil B, Visan L, Rodrigues L, Dunn P, Shewen PE, Macallum GE, Turner PV, Vogel TU.

J Immunother. 2013 May;36(4):238-47. doi: 10.1097/CJI.0b013e3182941813.

PMID:
23603858
12.

Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma.

Vogel TU, Visan L, Ljutic B, Gajewska B, Caterini J, Salha D, Wen T, He L, Parrington M, Cao SX, McNeil B, Sandhu D, Scollard N, Zhang L, Bradley B, Tang M, Lovitt C, Oomen R, Dunn P, Tartaglia J, Berinstein NL.

J Immunother. 2010 Oct;33(8):743-58. doi: 10.1097/CJI.0b013e3181eccc87.

PMID:
20842062
13.

Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239.

Vogel TU, Reynolds MR, Fuller DH, Vielhuber K, Shipley T, Fuller JT, Kunstman KJ, Sutter G, Marthas ML, Erfle V, Wolinsky SM, Wang C, Allison DB, Rud EW, Wilson N, Montefiori D, Altman JD, Watkins DI.

J Virol. 2003 Dec;77(24):13348-60.

14.

Escape in one of two cytotoxic T-lymphocyte epitopes bound by a high-frequency major histocompatibility complex class I molecule, Mamu-A*02: a paradigm for virus evolution and persistence?

Vogel TU, Friedrich TC, O'Connor DH, Rehrauer W, Dodds EJ, Hickman H, Hildebrand W, Sidney J, Sette A, Hughes A, Horton H, Vielhuber K, Rudersdorf R, De Souza IP, Reynolds MR, Allen TM, Wilson N, Watkins DI.

J Virol. 2002 Nov;76(22):11623-36.

15.

Differences between T cell epitopes recognized after immunization and after infection.

Vogel TU, Horton H, Fuller DH, Carter DK, Vielhuber K, O'Connor DH, Shipley T, Fuller J, Sutter G, Erfle V, Wilson N, Picker LJ, Watkins DI.

J Immunol. 2002 Oct 15;169(8):4511-21.

16.

Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239.

Horton H, Vogel TU, Carter DK, Vielhuber K, Fuller DH, Shipley T, Fuller JT, Kunstman KJ, Sutter G, Montefiori DC, Erfle V, Desrosiers RC, Wilson N, Picker LJ, Wolinsky SM, Wang C, Allison DB, Watkins DI.

J Virol. 2002 Jul;76(14):7187-202.

17.

Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model.

Earl PL, Wyatt LS, Montefiori DC, Bilska M, Woodward R, Markham PD, Malley JD, Vogel TU, Allen TM, Watkins DI, Miller N, Moss B.

Virology. 2002 Mar 15;294(2):270-81.

18.

Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection.

O'Connor DH, Allen TM, Vogel TU, Jing P, DeSouza IP, Dodds E, Dunphy EJ, Melsaether C, Mothé B, Yamamoto H, Horton H, Wilson N, Hughes AL, Watkins DI.

Nat Med. 2002 May;8(5):493-9.

PMID:
11984594
19.
20.

Dominance of CD8 responses specific for epitopes bound by a single major histocompatibility complex class I molecule during the acute phase of viral infection.

Mothé BR, Horton H, Carter DK, Allen TM, Liebl ME, Skinner P, Vogel TU, Fuenger S, Vielhuber K, Rehrauer W, Wilson N, Franchini G, Altman JD, Haase A, Picker LJ, Allison DB, Watkins DI.

J Virol. 2002 Jan;76(2):875-84.

21.

A common rhesus macaque MHC class I molecule which binds a cytotoxic T-lymphocyte epitope in Nef of simian immunodeficiency virus.

Horton H, Rehrauer W, Meek EC, Shultz MA, Piekarczyk MS, Jing P, Carter DK, Steffen SR, Calore B, Urvater JA, Vogel TU, Wilson NA, Watkins DI.

Immunogenetics. 2001 Jul;53(5):423-6. No abstract available.

PMID:
11486280
22.
23.

Rapid definition of five novel HLA-A*3002-restricted human immunodeficiency virus-specific cytotoxic T-lymphocyte epitopes by elispot and intracellular cytokine staining assays.

Goulder PJ, Addo MM, Altfeld MA, Rosenberg ES, Tang Y, Govender U, Mngqundaniso N, Annamalai K, Vogel TU, Hammond M, Bunce M, Coovadia HM, Walker BD.

J Virol. 2001 Feb;75(3):1339-47.

24.

CD8(+) lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule mamu-A*01: implications for vaccine design and testing.

Allen TM, Mothé BR, Sidney J, Jing P, Dzuris JL, Liebl ME, Vogel TU, O'Connor DH, Wang X, Wussow MC, Thomson JA, Altman JD, Watkins DI, Sette A.

J Virol. 2001 Jan;75(2):738-49.

25.

Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia.

Allen TM, O'Connor DH, Jing P, Dzuris JL, Mothé BR, Vogel TU, Dunphy E, Liebl ME, Emerson C, Wilson N, Kunstman KJ, Wang X, Allison DB, Hughes AL, Desrosiers RC, Altman JD, Wolinsky SM, Sette A, Watkins DI.

Nature. 2000 Sep 21;407(6802):386-90.

PMID:
11014195
26.

Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen.

Allen TM, Vogel TU, Fuller DH, Mothé BR, Steffen S, Boyson JE, Shipley T, Fuller J, Hanke T, Sette A, Altman JD, Moss B, McMichael AJ, Watkins DI.

J Immunol. 2000 May 1;164(9):4968-78.

27.

Major histocompatibility complex class I genes in primates: co-evolution with pathogens.

Vogel TU, Evans DT, Urvater JA, O'Connor DH, Hughes AL, Watkins DI.

Immunol Rev. 1999 Feb;167:327-37. Review.

PMID:
10319271
28.

Presence of circulating CTL induced by infection with wild-type or attenuated SIV and their correlation with protection from pathogenic SHIV challenge.

Vogel TU, Fournier J, Sherring A, Ko D, Parenteau M, Bogdanovic D, Mihowich J, Rud EW.

J Med Primatol. 1998 Apr-Jun;27(2-3):65-72.

PMID:
9747945

Supplemental Content

Loading ...
Support Center